We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+9.88%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.45B
AUM Growth
+$379M
Cap. Flow
+$62.7M
Cap. Flow %
1.15%
Top 10 Hldgs %
26.99%
Holding
161
New
18
Increased
65
Reduced
42
Closed
14

Top Buys

Rank Stock Value
1
DOCS icon
Doximity
DOCS
+$43.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$39.4M
3
LAD icon
Lithia Motors
LAD
+$30.5M
4
PANW icon
Palo Alto Networks
PANW
+$25.7M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$25.5M

Top Sells

Rank Stock Value
1
GTM
ZoomInfo Technologies
GTM
+$82.3M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$41.8M
3
IMVT icon
Immunovant
IMVT
+$40M
4
DV icon
DoubleVerify
DV
+$35.4M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 43.08%
2 Technology 23.47%
3 Industrials 13.06%
4 Consumer Discretionary 7.01%
5 Utilities 3.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHW icon
101
Sherwin-Williams
SHW
$82.5B
$14.6M 0.27%
64,734
+11,287
+21% +$2.58M
AKRO
102
DELISTED
Akero Therapeutics
AKRO
$14.5M 0.27%
+379,120
New +$16.9M
RARE icon
103
Ultragenyx Pharmaceutical
RARE
$2.44B
$14.4M 0.26%
359,000
– –
IEX icon
104
IDEX
IEX
$16.9B
$14.1M 0.26%
61,154
-8,003
-12% -$1.82M
BEAM icon
105
Beam Therapeutics
BEAM
$2.63B
$14.1M 0.26%
459,203
+192,178
+72% +$7.58M
AESC
106
DELISTED
The AES Corporation
AESC
– –
-171,200
Closed -$16M
MRTX
107
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.8M 0.25%
371,102
+167,502
+82% +$7.53M
NBIX icon
108
Neurocrine Biosciences
NBIX
$16.9B
$13.7M 0.25%
135,000
– –
AMLX icon
109
Amylyx Pharmaceuticals
AMLX
$2.16B
$13.4M 0.25%
458,054
+208,054
+83% +$7.23M
ESI icon
110
Element Solutions
ESI
$8.87B
$13.4M 0.25%
693,556
-277,444
-29% -$5.47M
ZIP icon
111
ZipRecruiter
ZIP
$315M
$13M 0.24%
+817,475
New +$14.8M
KROS icon
112
Keros Therapeutics
KROS
$196M
$12.8M 0.24%
+300,000
New +$15.2M
ROIV icon
113
Roivant Sciences
ROIV
$24.4B
$12.5M 0.23%
1,690,300
– –
GXO icon
114
GXO Logistics
GXO
$5.75B
$11.1M 0.2%
220,075
+75
+0% +$3.73K
EHC icon
115
Encompass Health
EHC
$11B
$10.3M 0.19%
189,979
-4,516
-2% -$263K
ETNB
116
DELISTED
89bio
ETNB
$9.78M 0.18%
+642,073
New +$8.37M
APTV.PRA
117
DELISTED
Aptiv PLC 5.50% Series A Mandatory Convertible Preferred Shares
APTV.PRA
– –
0
– –
BCRX icon
118
BioCryst Pharmaceuticals
BCRX
$2.28B
$9.2M 0.17%
+1,102,889
New +$10.6M
RCM
119
DELISTED
R1 RCM Inc. Common Stock
RCM
$8.93M 0.16%
+595,569
New +$8.15M
WEC icon
120
WEC Energy
WEC
$35.9B
$8.93M 0.16%
94,165
-86,027
-48% -$7.96M
CERE
121
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$7.61M 0.14%
+312,000
New +$9.16M
DNLI icon
122
Denali Therapeutics
DNLI
$3.71B
$7.22M 0.13%
+313,407
New +$8.63M
ANNX icon
123
Annexon
ANNX
$832M
$7.19M 0.13%
1,867,250
-1,759,258
-49% -$9.68M
CRNX icon
124
Crinetics Pharmaceuticals
CRNX
$8.87B
$6.98M 0.13%
+434,768
New +$8.05M
CMS icon
125
CMS Energy
CMS
$22.7B
$6.91M 0.13%
112,531
-82,969
-42% -$5.1M
3 4
5
6 7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Eventide Asset Management held 161 positions worth $5.45B, up 7.5% from $5.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management's Q1 2023 filing shows 18 new, 65 increased, 42 reduced and 14 closed positions. Its largest new stake was Lithia Motors: 125,499 shares worth $28.7M. The largest sale was ZoomInfo Technologies, an estimated $82.3M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q1 2023 buy was Lithia Motors: 125,499 shares worth $28.7M.
  • Eventide Asset Management added most to Doximity in Q1 2023, an estimated $43.7M increase.
  • Eventide Asset Management's biggest Q1 2023 reduction was ZoomInfo Technologies, cutting an estimated $82.3M.
  • Eventide Asset Management fully exited Bicycle Therapeutics in Q1 2023, selling an estimated $25.3M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $5.45B portfolio in Q1 2023.
  • Eventide Asset Management opened 18 new positions and closed 14 in Q1 2023.
  • Eventide Asset Management's portfolio value rose 7.5% quarter-over-quarter to $5.45B.

Based on Eventide Asset Management's 13F filing for Q1 2023, filed 15 May 2023.